Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAytuluk, Hande Gurbuz
dc.contributor.authorTopcu, Hulya
dc.date.accessioned2021-11-01T15:05:12Z
dc.date.available2021-11-01T15:05:12Z
dc.date.issued2020
dc.identifier.issn1130-1473
dc.identifier.issn2340-6305
dc.identifier.urihttps://doi.org/10.1016/j.neucir.2019.12.003
dc.identifier.urihttps://hdl.handle.net/11491/7170
dc.description.abstractObjectives: To evaluate the incidence of severe potassium disturbances during barbiturate coma therapy in patients with severe traumatic brain injury (TBI), and the characteristics of these patients. Methods: The study comprised 37 patients with severe TBI who were treated for barbiturate coma between 2015 and 2017 in level 3 intensive care units of two hospitals. Results: No potassium disturbance occurred in 14 patients. Seventeen patients developed mild-moderate hypokalemia (2.6-3.5 mEq/L), and 6 patients developed severe hypokalemia (<2.5 mEq/L) following the induction of barbiturate therapy. The incidence of mild-tosevere barbiturate-induced hypokalemia was 62.2% and the rate of severe hypokalemia was 16.2%. The mean potassium supply per day during thiopentone therapy was statistically significantly different between patients with mild-to-moderate hypokalemic and those with severe hypokalemic (p < 0.001). Four of 6 patients with severe hypokalemia developed rebound hyperkalemia exceeding 6 mEq/L following the cessation of barbiturate infusion. The nadir potassium concentration was 1.5 mEq/L and the highest value was 6.8 mEq/L. The mean time to reach nadir potassium concentrations was 2.8 days. The mortality rate of the 6 patients was 66.7%. Of the 2 survivors of severe hypokalemia, the Glasgow Outcome Scale (GOS) on discharge and the extended GOS one year after the trauma were 5 and 8 respectively. Conclusions: Severe hypokalemia refractory to medical treatment and rebound hyperkalemia is a serious adverse effect of thiopentone coma therapy in patients with severe TBI. Excessive and aggressive potassium replacement during the barbiturate-induced hypokalemia period must be avoided. Weaning barbiturate treatment over time may be advantageous in the management of severe serum potassium disturbances. (C) 2020 Sociedad Espanola de Neurocirugia. Published by Elsevier Espana, S.L.U. All rights reserved.en_US
dc.language.isoengen_US
dc.publisherElsevier Espana Sluen_US
dc.relation.ispartofNeurocirugiaen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBarbituratesen_US
dc.subjectBrain injuriesen_US
dc.subjectTraumaticen_US
dc.subjectHyperkalemiaen_US
dc.subjectHypokalemiaen_US
dc.subjectPotassiumen_US
dc.subjectThiopentalen_US
dc.titleSevere hypokalemia and rebound hyperkalemia during barbiturate coma in patients with severe traumatic brain injuryen_US
dc.typearticleen_US
dc.department[Belirlenecek]en_US
dc.authoridGurbuz, Hande / 0000-0002-3562-9517
dc.identifier.volume31en_US
dc.identifier.issue5en_US
dc.identifier.startpage216en_US
dc.identifier.endpage222en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.department-temp[Aytuluk, Hande Gurbuz] Univ Hlth Sci, Derince Training & Res Hosp, Dept Anesthesiol & Reanimat, Kocaeli, Turkey; [Aytuluk, Hande Gurbuz] Kocaeli State Hosp, Dept Anesthesiol & Reanimat, Kocaeli, Turkey; [Topcu, Hulya] Hitit Univ, Erol Olcok Training & Res Hosp, Dept Anesthesiol & Reanimat, Corum, Turkeyen_US
dc.contributor.institutionauthor[Belirlenecek]
dc.identifier.doi10.1016/j.neucir.2019.12.003
dc.authorwosidGurbuz, Hande / U-3068-2018
dc.description.wospublicationidWOS:000563330000002en_US
dc.description.scopuspublicationid2-s2.0-85081018563en_US
dc.description.pubmedpublicationidPubMed: 32146086en_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster